Biogen Stock Forecast, Price & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have decreased by 7.1% and is now trading at $273.28.
View which stocks have been most impacted by COVID-19.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) released its earnings results on Wednesday, July, 22nd. The biotechnology company reported $10.26 EPS for the quarter, beating the Zacks' consensus estimate of $8.03 by $2.23. The biotechnology company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.44 billion. Biogen had a return on equity of 50.10% and a net margin of 40.91%. During the same period in the previous year, the firm earned $9.15 earnings per share.
View Biogen's earnings history.

Biogen announced that its Board of Directors has authorized a share repurchase program on Monday, December 23rd 2019, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.

Biogen updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share (EPS) guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

31 analysts have issued 1 year target prices for Biogen's stock. Their forecasts range from $228.00 to $392.00. On average, they expect Biogen's stock price to reach $310.39 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price.
View analysts' price targets for Biogen.

Biogen saw a increase in short interest in August. As of August 31st, there was short interest totaling 3,310,000 shares, an increase of 39.1% from the August 15th total of 2,380,000 shares. Based on an average trading volume of 1,500,000 shares, the short-interest ratio is presently 2.2 days. Currently, 2.1% of the company's stock are short sold.
View Biogen's Short Interest.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Micron Technology (MU), Intel (INTC) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.22%), Vanguard Group Inc. (8.13%), Bank of New York Mellon Corp (1.46%), AQR Capital Management LLC (1.41%), Goldman Sachs Group Inc. (0.84%) and FMR LLC (0.72%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., FMR LLC, Jacobs Levy Equity Management Inc., Banco Santander S.A., Ikarian Capital LLC, Toronto Dominion Bank, and Charles Schwab Investment Management Inc.. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, AJO LP, Orbimed Advisors LLC, Assetmark Inc., Assenagon Asset Management S.A., PGGM Investments, Robeco Institutional Asset Management B.V., and AQR Capital Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $273.28.

Biogen has a market capitalization of $43.26 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]